The BRAF/MEK inhibitor combination of encorafenib (Braftovi) and binimetinib (Mekinist) has demonstrated long-term benefits in patients with BRAF V600-mutant melanoma, according to 5-year analysis results from the COLUMBUS study (NCT01909453). The safety profile of the combination was also consistent with prior reports, according to the published findings.
Clinical Trials
Recent Trial Data on Tebentafusp in Metastatic Uveal Melanoma
Ryan Sullivan, MD: Now is a good time to talk a little about the clinical trial data, and then we can have a discussion about the toxicities and the management of the toxicities.
Encorafenib Plus Binimetinib Improves Long-Term PFS, OS in BRAF V600-Mutant Melanoma
Encorafenib plus binimetinib can provide long-term benefits in patients with BRAF V600-mutant melanoma, according to research published in the Journal of Clinical Oncology.
Amgen’s viral cancer vaccine T-Vec tackles melanoma tumors in PhIII
Amgen ($AMGN) has stepped up with a new round of late-stage data supporting its cancer-fighting viral vaccine talimogene laherparepvec, better known as T-Vec.